** Brokerage Raymond James resumes coverage on drugmaker BridgeBio Pharma BBIO.O with "outperform" rating; sets PT at $57, a 66.4% upside to the stock's last close
** Brokerage anticipates BBIO's launch of heart disease drug Attruby to be faster than expected, even with a significant discount on revenues after 2028 due to potential pricing pressure from the loss of exclusivity for Pfizer's PFE.N tafamidis
** "We expect it to gain meaningful market share in the newly diagnosed population," brokerage adds
** BBIO can leverage its drugs Encaleret and BBP-418 to form partnerships and improve finances — brokerage
** 14 out of 16 brokerages rate the stock "buy" or higher, 2 rate it "hold", per data compiled by LSEG
** Stock has fallen 4.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.